FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281375> ?p ?o ?g. }

• W4379281375 endingPage "9105" @default.
• W4379281375 startingPage "9105" @default.
• W4379281375 abstract "9105 Background: Currently, limited targeted therapies are available for HER2 mutant NSCLC patients. Previous studies have shown the antitumor activity of pyrotinib in advanced NSCLC patients with HER2 mutations. Inetetamab is a recombinant humanized anti-HER2 monoclonal antibody. Whether inetetamab combined with pyrotinib could show manageable safety and more active antitumor activity remains unknown. This study was designed to evaluate the safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with advanced NSCLC. Methods: This study was an open-label, phase Ib study. The HER2 mutant patients with locally advanced or metastatic NSCLC were assigned to receive inetetamab combined with pyrotinib. The study consisted of dose-escalation part and dose-expansion part. During dose-escalation period, the parallel 3+3 dose-escalation design was used to determine the dose-limiting toxicity (DLT). Inetetamab was administered every 3 weeks (8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles) with pyrotinib (dose-escalation part, 240mg QD, 320mg QD; dose-expansion part, 320mg QD). Primary endpoint of the study was DLT dosage and safety. The DLT was assessed during the 21-day DLT evaluation period after the first dose. Secondary endpoints included objective response rate (ORR), disease control rate (DCR), progression free survival and overall survival. Results: Between August 6, 2021, and August 25, 2022, 48 patients were enrolled. No DLT occurred during pyrotinib 240mg and 320mg escalation period. Therefore, pyrotinib 320mg was chosen as expansion dose. The most common treatment-related adverse events (TRAEs) were diarrhea (66.7% [2/3] in pyrotinib 240mg group, 95.6% [43/45] in pyrotinib 320mg group), rash (66.7% [2/3] in pyrotinib 240mg group, 22.2% [10/45] in pyrotinib 320mg group) and vomiting (0 in pyrotinib 240mg group, 24.4% [11/45] in pyrotinib 320mg group). TRAEs were generally Grade (G) 1-2. Only 7 patients reported G3 TRAE (1 in pyrotinib 240mg group, 6 in pyrotinib 320mg group). The preliminary efficacy was shown in the table below. The ORR and DCR of group receiving inetetamab with pyrotinib 240mg were 0% and 66.7%, respectively. The ORR and DCR of inetetamab with pyrotinib 320mg group were 36.6% and 85.4% respectively. The relationship between different mutation subtypes or co-mutations and efficacy will be updated during the conference reports. Conclusions: The preliminary data of inetetamab in combination with pyrotinib showed manageable safety and compelling antitumor activity in advanced NSCLC patients harboring HER2 mutations. Clinical trial information: NCT05016544 . [Table: see text]" @default.
• W4379281375 created "2023-06-05" @default.
• W4379281375 creator A5003608372 @default.
• W4379281375 creator A5013715130 @default.
• W4379281375 creator A5020252828 @default.
• W4379281375 creator A5023899283 @default.
• W4379281375 creator A5045067652 @default.
• W4379281375 creator A5046131158 @default.
• W4379281375 creator A5057612778 @default.
• W4379281375 creator A5062604492 @default.
• W4379281375 creator A5066716873 @default.
• W4379281375 creator A5067253443 @default.
• W4379281375 creator A5070121957 @default.
• W4379281375 creator A5090962174 @default.
• W4379281375 creator A5091143438 @default.
• W4379281375 creator A5092083287 @default.
• W4379281375 date "2023-06-01" @default.
• W4379281375 modified "2023-10-03" @default.
• W4379281375 title "Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial." @default.
• W4379281375 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.9105" @default.
• W4379281375 hasPublicationYear "2023" @default.
• W4379281375 type Work @default.
• W4379281375 citedByCount "1" @default.
• W4379281375 crossrefType "journal-article" @default.
• W4379281375 hasAuthorship W4379281375A5003608372 @default.
• W4379281375 hasAuthorship W4379281375A5013715130 @default.
• W4379281375 hasAuthorship W4379281375A5020252828 @default.
• W4379281375 hasAuthorship W4379281375A5023899283 @default.
• W4379281375 hasAuthorship W4379281375A5045067652 @default.
• W4379281375 hasAuthorship W4379281375A5046131158 @default.
• W4379281375 hasAuthorship W4379281375A5057612778 @default.
• W4379281375 hasAuthorship W4379281375A5062604492 @default.
• W4379281375 hasAuthorship W4379281375A5066716873 @default.
• W4379281375 hasAuthorship W4379281375A5067253443 @default.
• W4379281375 hasAuthorship W4379281375A5070121957 @default.
• W4379281375 hasAuthorship W4379281375A5090962174 @default.
• W4379281375 hasAuthorship W4379281375A5091143438 @default.
• W4379281375 hasAuthorship W4379281375A5092083287 @default.
• W4379281375 hasConcept C126322002 @default.
• W4379281375 hasConcept C143998085 @default.
• W4379281375 hasConcept C197934379 @default.
• W4379281375 hasConcept C203092338 @default.
• W4379281375 hasConcept C2776256026 @default.
• W4379281375 hasConcept C29730261 @default.
• W4379281375 hasConcept C31760486 @default.
• W4379281375 hasConcept C535046627 @default.
• W4379281375 hasConcept C71924100 @default.
• W4379281375 hasConceptScore W4379281375C126322002 @default.
• W4379281375 hasConceptScore W4379281375C143998085 @default.
• W4379281375 hasConceptScore W4379281375C197934379 @default.
• W4379281375 hasConceptScore W4379281375C203092338 @default.
• W4379281375 hasConceptScore W4379281375C2776256026 @default.
• W4379281375 hasConceptScore W4379281375C29730261 @default.
• W4379281375 hasConceptScore W4379281375C31760486 @default.
• W4379281375 hasConceptScore W4379281375C535046627 @default.
• W4379281375 hasConceptScore W4379281375C71924100 @default.
• W4379281375 hasIssue "16_suppl" @default.
• W4379281375 hasLocation W43792813751 @default.
• W4379281375 hasOpenAccess W4379281375 @default.
• W4379281375 hasPrimaryLocation W43792813751 @default.
• W4379281375 hasRelatedWork W2032912323 @default.
• W4379281375 hasRelatedWork W2049705798 @default.
• W4379281375 hasRelatedWork W2126488520 @default.
• W4379281375 hasRelatedWork W2356374822 @default.
• W4379281375 hasRelatedWork W2372561159 @default.
• W4379281375 hasRelatedWork W2390152934 @default.
• W4379281375 hasRelatedWork W2949323893 @default.
• W4379281375 hasRelatedWork W3177224496 @default.
• W4379281375 hasRelatedWork W4377093556 @default.
• W4379281375 hasRelatedWork W4384922324 @default.
• W4379281375 hasVolume "41" @default.
• W4379281375 isParatext "false" @default.
• W4379281375 isRetracted "false" @default.
• W4379281375 workType "article" @default.